论文信息 - Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study - 字舞流文

Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study

R. McKelvie | P. Dehghani | A. Bagai | A. Yan | M. Tan | S. Goodman | J. Dery | S. Lutchmedial | S. Lavi | T. Cieza | Ashish Patel | N. Suskin | Andrew Mathew | A. Lavoie | T. Huynh | C. Fordyce | M. Heffernan | S. Jedrzkiewicz | M. Madan | S. Ahmed | C. Barry | T. Sedlak | S. Radhakrishnan | R. Philipp | N. Brunner | R. Khan | S. Kassam | Hahn Hoe Kim